Sign in
SuspendedNo phase

Genetesis Accelerated Registry

Key facts

Who runs it
Genetesis Inc.
Where
Mason, United StatesSee the site
Trial code
Status
Suspended
People taking part
500 people, planned
Started
27 Jan 2021
Ended
Jul 2024
Type of study
Observational
Treatments tested
  • CardioFlux
Record updated
23 February 2023
Why it stopped
Resourcing

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • ≥ 18 years of age at the time of enrollment

Who cannot take part

  • Patients with present with or have reasonable clinical suspicion of any acute coronary syndrome for which delayed intervention could increase the risk or magnitude of damaged myocardium
  • < 18 years of age
  • Patients unable to fit into device
  • Non-ambulatory patients
  • Patients with claustrophobia or unable to lie supine for 5 minutes
  • Pregnant women
  • Poor candidate for follow-up (e.g. no access to phone)
  • Prisoners
  • Patients with a language barrier/language difficulties

Where in United States

  • Genetesis FacilityMason, United States

About the trial

What the trial wants to find out

Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood pressure, high cholesterol, family history of heart disease, and diabetes. The purpose of the Genetesis Accelerated Registry (GEAR) study is to understand the potential for magnetocardiography to be utilized as a diagnostic, screening or surveillance tool for heart disease in healthy and non-healthy volunteers. Magnetocardiography (MCG) is a diagnostic method that analyzes and records the magnetic fields of the heart for the detection of various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 500 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.

The group in the trial

  • GEAR cohort

    This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.

    Treatment: CardioFlux

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 February 2023